Education
About Us
Working with TipRanks
Follow Us
Cell Source (CLCS)
:CLCS
CLCS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.14 - $0.84
Previous CloseN/A
Volume3.40K
Average Volume (3M)4.45K
Market Cap
$12.82M
Enterprise Value$33.73M
Total Cash (Recent Filing)$22.99K
Total Debt (Recent Filing)$9.78M
Price to Earnings (P/E)―
Beta-532.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding43,468,185
10 Day Avg. Volume3,188
30 Day Avg. Volume4,450
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-5.43
Price to Sales (P/S)0.00
P/FCF Ratio-12.04
Enterprise Value/Market Cap2.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cell Source News
CLCS FAQ
What was Cell Source ’s price range in the past 12 months?
Cell Source lowest stock price was $0.14 and its highest was $0.84 in the past 12 months.
What is Cell Source ’s market cap?
Cell Source ’s market cap is $12.82M.
When is Cell Source ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cell Source ’s earnings last quarter?
Currently, no data Available
Is Cell Source overvalued?
According to Wall Street analysts Cell Source ’s price is currently Overvalued.
Does Cell Source pay dividends?
Cell Source does not currently pay dividends.
What is Cell Source ’s EPS estimate?
Cell Source ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cell Source have?
Cell Source has 43,468,185 shares outstanding.
What happened to Cell Source ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cell Source ?
Currently, no hedge funds are holding shares in CLCS
Company Description
Cell Source
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Technical Analysis
Eterna Therapeutics
―
GeoVax Labs
―
Synlogic
―
Moleculin Biotech
―
Marker Therapeutics
―